Bionaltech proposes acquisition of Curevac: Secure deal in Tübingen

Biontech Swallows Curevac: Tübingen's Biotech Boost

Pharmaceutical giant BioNTech to take over CureVac; Tuebingen headquarters assured - Bionaltech proposes acquisition of Curevac: Secure deal in Tübingen

Get ready for a game-changer in the world of biotech! The Biontech takeover of Curevac is set to reshape the Tübingen biotech scene, according to the Baden-Württemberg Health Economy Agency Biopro.

Business manager Barbara Jonischkeit, speaking in Stuttgart, called this move a strategic no-brainer. The merger not only amps up Biontech's dominance in the mRNA tech field but also secures Tübingen's long-term future, she added.

The deal's main objective is to ramp up research, development, and production of innovative mRNA-based cancer immunotherapies in Tübingen. This move is expected to beef up skilled jobs and scientific prowess in the region. According to Jonischkeit, this acquisition is a beacon for the sustained promotion of the innovation hub that is Germany.

It's important to note that around 700 employees, with over 80% based in the Tübingen headquarters, are part of Curevac. Biontech has been impressed by the site's technology achievements over the past 25 years, and they're committed to making Tübingen a significant player in the mRNA world within their group.

The Stuttgart-Tübingen-Reutlingen region is already a formidable biotech hub, boasting more than 70 biotech and pharmaceutical companies. The high concentration of specialized firms makes the region an excellent playground for cooperation between pharmaceutical and biotech companies. Add to that a robust research landscape that nurtures collaboration between science, start-ups, and established players.

Stay tuned, as Biontech, based in Mainz, plans to acquire all of Curevac's shares in a deal worth billions. This is the second billion-dollar deal Biontech has announced in quick succession.

In the 2020 race for a COVID-19 vaccine, both Biontech and Curevac were in the running. While Biontech triumphed, Curevac didn't make the cut. Regardless, the Tübingen site is safe – it's set to play a key role in the Biontech group's mRNA domain.

Now, let's dive into the finer details: The integration aims to harness the complementary scientific talents of both companies, leading to further innovation in mRNA technology. Biontech's takeover also positions Tübingen as a major hub for developing cancer treatments, leveraging mRNA tech to create groundbreaking therapies.

The merger is poised to boost investment in the Tübingen site, potentially generating new job opportunities and stimulating the local economy. This could attract additional talent and partnerships, further enhancing Tübingen's reputation as a biotech hotspot.

The strategic merger between Biontech and Curevac, driven by shared interests in mRNA technology, will not only elevate Tübingen as a significant player in cancer treatment research but also serve as a foundation for advanced vocational training in the science and technology sectors, nurturing a skilled workforce in the region. As the Biontech group invests in Curevac, Tübingen is expected to become a global hub for mRNA-based innovation, attracting science, start-ups, and established players alike.

Read also: